Hanall Biopharma Co., Ltd.

Green Cross Holdings Corporation

Jae Woon Son

Sung Wuk Kim

Sung Soo Jun

Young Gwan Jo

Ja Seong Koo

Ju Ho Lee

Hyo Jin Kim

Ji Yoon Park

Yong Won Shin

Jun Sic Kim

A method for purifying fibrinogen includes steps of: (a) precipitating fibrinogen of a fibrinogen-containing solution by adding glycine to the solution for a concentration of glycine to be 1.5 to 2.5M, and then removing a supernatant and recovering a precipitate (1glycine precipitation); (b) dissolving the precipitate of 1glycine precipitation of step (a) in a dissolution buffer to obtain a solution, precipitating the solution by adding glycine thereto for a concentration of glycine to be 0.2 to 1.2M, and recovering a supernatant (2glycine precipitation); (c) precipitating the supernatant of step (b) by adding glycine thereto for a concentration of glycine to be 1.5 to 2.5M, and recovering a precipitate (3glycine precipitation); and (d) dissolving the precipitate of step (c) in a dissolution buffer to obtain a solution, and subjecting the solution to nanofiltration using a nanofilter.

Method for purifying fibrinogen

Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors

Disclosed herein is a combination therapy and a combination preparation of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor characterized in that the angiotensin-II-receptor blocker is absorbed substantially later than the HMG-CoA reductase inhibitor. As the angiotensin-II-receptor blocker and the HMG-CoA reductase inhibitor are released at different times, the present combination therapy prevents competitive inhibition between the two drugs and side effects, as well as simultaneously provides synergistic effects for each active ingredient and convenience of taking the drugs.

Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor

Growing community of inventors

Suwon-si, South Korea

Jae Woon Son